| アブストラクト | OBJECTIVES: Immunosuppressive therapy is the mainstay of treatment for child-onset systemic lupus erythematosus (cSLE). Since epidemiological data on Japanese cSLE patients are not available, we evaluated the trends in how treatment choices have changed over time in Japan. METHODS: Using the Japanese health insurance database provided by Medical Data Vision Co., Ltd, we identified cSLE patients and evaluated changes in the use of corticosteroids and immunosuppressive medications and maximum daily doses of prednisolone from 2009 to 2018. RESULTS: Of 182 cSLE patients, 86% were female, and the median age was 14 years. Oral prednisolone was used in more than 97% of cSLE patients during the study period, and the median of the maximum daily dose in each patient decreased over time. Intravenous cyclophosphamide was used less frequently after 2016, while mycophenolate mofetil and hydroxychloroquine were used frequently after 2016. The use of mizoribine reduced after 2014, whereas the other immunosuppressive medications showed no significant change over time; the use of biological agents was very limited. CONCLUSIONS: Oral prednisolone was the mainstay of treatment for cSLE, and the maximum daily dose has reduced over the past decade. The most frequently prescribed immunosuppressive therapy has shifted to mycophenolate mofetil over time. |
|---|
| ジャーナル名 | Modern rheumatology |
|---|
| Pubmed追加日 | 2021/12/16 |
|---|
| 投稿者 | Kishi, Takayuki; Sakai, Ryoko; Tani, Yumi; Nagata, Satoru; Katsumata, Yasuhiro; Miyamae, Takako; Harigai, Masayoshi |
|---|
| 組織名 | Department of Pediatrics, Tokyo Women's Medical University School of Medicine,;Tokyo, Japan.;Department of Rheumatology, Tokyo Women's Medical University School of Medicine, |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/34908147/ |
|---|
